HPMA Copolymer-Conjugated Pirarubicin in Multimodal Treatment of a Patient with Stage IV Prostate Cancer and Extensive Lung and Bone Metastases - PubMed (original) (raw)

Case Reports

doi: 10.1007/s11523-015-0379-4.

Shintaro Yanazume 2, Hideaki Nakamura 3, Tomáš Etrych 4, Petr Chytil 4, Karel Ulbrich 4, Jun Fang 3, Takeshi Arimura 5, Tsutomu Douchi 6, Hiroaki Kobayashi 6, Michiaki Ikoma 7, Hiroshi Maeda 8

Affiliations

Case Reports

HPMA Copolymer-Conjugated Pirarubicin in Multimodal Treatment of a Patient with Stage IV Prostate Cancer and Extensive Lung and Bone Metastases

Haruhiko Dozono et al. Target Oncol. 2016 Feb.

Abstract

Nanomedicine allows achievement of tumor-selective drug delivery because of the enhanced permeability and retention (EPR) effect of solid tumors. We report here the first clinical application of a new agent-HPMA copolymer-conjugated pirarubicin (P-THP)-with a molecular size of about 8 nm, or 38.5 kDa. A patient had advanced prostate cancer with multiple metastases in the lung, pelvis, femur, and perhaps the sacrum. In April 2013, this 60-year-old patient started treatment with leuprorelin and estradiol, which continued until July 2014, but the patient became refractory to this treatment. So the patient underwent proton beam radiotherapy targeted to the primary prostate cancer, and P-THP was administered for numerous metastatic tumor nodules concomitantly with radiotherapy. This combination therapy had remarkable results, with complete remission of multiple metastases in the lung and bone. The prostate-specific antigen (PSA) value was decreased from about 1000 ng/mL on April 30, 2013, to about 100 ng/mL on June 24, 2013, with hormone therapy, but rose again to 964.2 ng/mL and then to 1472 ng/mL in July 2013, during leuprorelin administration. P-THP treatment administered concomitantly with proton beam irradiation was started in August 2013. The PSA value was decreased to 102 ng/mL on August 26, 2013, and then to 0.971 ng/mL on October 8, 2013, and 0.277 ng/mL on January 15, 2015. The P-THP doses ranged from 30 to 75 mg of free THP equivalent/patient every 2-3 weeks without signs of serious toxicity, such as cardiovascular side effects or a reduction in quality of life. No evidence of relapse was found more than 20 months after P-THP administration. This case demonstrates the value of hydrazone-bonded polymeric drugs in multimodal therapy.

PubMed Disclaimer

References

    1. J Clin Oncol. 2008 Jan 10;26(2):242-5 - PubMed
    1. J Control Release. 2011 Nov 7;155(3):367-75 - PubMed
    1. Cancer. 1984 Feb 1;53(3):406-10 - PubMed
    1. Cancer. 1992 Mar 15;69(6):1440-4 - PubMed
    1. Adv Drug Deliv Rev. 2010 Feb 17;62(2):122-49 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources